Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers

Sustained treatment of estrogen receptor (ER)-positive breast cancer with ER-targeting drugs results in ER mutations and refractory unresponsive cancers. Androgen receptor (AR), which is expressed in 80%–95% of ER-positive breast cancers, could serve as an alternate therapeutic target. Although AR a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponnusamy, Suriyan, Asemota, Sarah, Schwartzberg, Lee S., Guestini, Fouzia, McNamara, Keely M., Pierobon, Mariaelena, Font-Tello, Alba, Qiu, Xintao, Xie, Yingtian, Rao, Prakash K., Thiyagarajan, Thirumagal, Grimes, Brandy, Johnson, Daniel L., Fleming, Martin D., Pritchard, Frances E., Berry, Michael P., Oswaks, Roy, Fine, Richard E., Brown, Myles, Sasano, Hironobu, Petricoin, Emanuel F., Long, Henry W., Narayanan, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889594/
https://www.ncbi.nlm.nih.gov/pubmed/31698248
http://dx.doi.org/10.1016/j.isci.2019.10.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889594/
https://www.ncbi.nlm.nih.gov/pubmed/31698248
http://dx.doi.org/10.1016/j.isci.2019.10.038

Ejemplares similares